I'm completely new to Cadence. I've been able to run a very simple simulation with the -gui option. Simvision opens, I add the variables to the waveform viewer, and press run. All is good.

I don't understand the flow when using the -nogui option. It appears that the simulation runs and returns control to the OS. When I launch Simvision, is there a database or file that I can open to display the already-simulated data?

My command is of the form:

xrun -gui -64bit -sv -access +rwc -top tb_top.sv <src files>

Read through this blog to know more about the new Reliability Report view in Virtuoso ADE Assembler and Virtuoso ADE Explorer.(read more)

Cyprus is ranked first in fDi’s Island Economies of the Future rankings, followed by the Dominican Republic and Sri Lanka. Cathy Mullan and Naomi Davies detail the results.

The Bank of Cyprus (BoC) on Tuesday reported a profit after tax of €401 million for the first nine months of 2024, representing a 15 per cent increase year-on-year. According to the bank’s latest financial results, €131 million of this amount was generated during the third quarter. “We continue to generate strong financial and operational […]

Title: Whiplash May Result in Delayed Jaw Pain
Category: Health News
Created: 8/31/2007 12:00:00 AM
Last Editorial Review: 8/31/2007 12:00:00 AM

Title: Financial Incentives May Speed Radiology Test Results
Category: Health News
Created: 8/20/2010 2:10:00 PM
Last Editorial Review: 8/23/2010 12:00:00 AM

Title: Missed Diagnoses in ICU Often Have Deadly Results: Review
Category: Health News
Created: 8/28/2012 2:05:00 PM
Last Editorial Review: 8/29/2012 12:00:00 AM

Title: False-Positive Mammogram Result Traumatic for Most Women: Study
Category: Health News
Created: 8/26/2015 12:00:00 AM
Last Editorial Review: 8/26/2015 12:00:00 AM

ABSTRACTIntroduction:Since the health information system (HIS) in public health care services in Serbia was introduced in 2009, it has gradually expanded. However, it is unclear how well the HIS components have developed and the whole system’s stage of maturity.Method:In June–September 2021, a maturity assessment of the Serbian HIS was conducted for the first time using the HIS Stages of Continuous Improvement (SOCI) toolkit. The toolkit measures HIS status across 5 HIS domains: leadership and governance, management and workforce, information and communication technology (ICT), standards and interoperability, and data quality and use. The domains were further divided into 13 components and 39 subcomponents whose maturity stage was assessed on a 5-point Likert scale, indicating the level of development: (1) emerging/ad hoc; (2) repeatable; (3) defined; (4) managed; and (5) optimized. The toolkit was applied in a working group of 32 professionals and experts who were engaged in developing the new national eHealth strategy and action plan.Results:The overall maturity score of the Serbian HIS was 1.6, which indicates a low level. The highest baseline score (2) was given to the standards and interoperability domain, and the lowest (1.1) was given to ICT infrastructure. The remaining 3 domains (leadership and governance, Management and Workforce, and Data Quality and Use) were similarly rated (1.7, 1.7, and 1.6, respectively).Conclusion:A baseline assessment of the maturity level of Serbian HIS indicates that the majority of components are between the emerging/ad hoc stage and repeatable, which represent isolated, ad hoc efforts, with some basic processes in place and existing and accessible policies. This exercise provided an opportunity to address identified weaknesses in the upcoming national eHealth strategy.

The role of somatostatin receptor (SSTR) PET/CT, using ⁶⁸Ga-based tracers or [⁶⁴Cu]Cu-DOTATATE (⁶⁴Cu-DOTATATE), in the management of patients with neuroendocrine neoplasm (NEN) is guided by appropriate use criteria (AUC). In this study, we performed systematic analyses of referral patterns and image findings of routine ⁶⁴Cu-DOTATATE PET/CT scans to support AUC development. Methods: We included all clinical routine ⁶⁴Cu-DOTATATE PET/CT scans performed between April 10, 2018 (start of clinical use), and May 2, 2022, at Copenhagen University Hospital–Rigshospitalet. We reviewed the referral text and image report of each scan and classified the indication according to clinical scenarios as listed in the AUC. Results: In total, 1,290 patients underwent 2,249 ⁶⁴Cu-DOTATATE PET/CT scans. Monitoring of patients with NEN seen both on conventional imaging and on SSTR PET without clinical evidence of progression was the most common indication (defined as "may be appropriate" in the AUC) and accounted for 703 (31.3%) scans. Initial staging after NEN diagnosis ("appropriate" in the AUC) and restaging after curative-intent surgery ("may be appropriate" in the AUC) accounted for 221 (9.8%) and 241 (10.7%) scans, respectively. Selection of patients eligible for peptide receptor radionuclide therapy ("appropriate" in the AUC) and restaging after peptide receptor radionuclide therapy completion ("appropriate" in the AUC) accounted for 95 (4.2%) and 115 (5.1%) scans, respectively. The number of scans performed for indications not defined in the AUC was 371 (16.5%). Image result analysis revealed no disease in 669 scans (29.7%), stable disease in 582 (25.9%), and progression in 461 (20.5%). In 99 of the 461 (21.5%) scans, progression was detected on PET but not on CT. Conclusion: Our study provided real-life data that may contribute to support development of ⁶⁴Cu-DOTATATE/SSTR PET/CT guidelines including AUC. Some scenarios listed as "may be appropriate" in the current AUC were frequent in our data. Monitoring of patients with NEN without clinical evidence of progression was the most frequent indication for ⁶⁴Cu-DOTATATE PET/CT, in which disease progression was detected in more than one third, and a large proportion was visible by PET only. We therefore conclude that this scenario could potentially be classified as appropriate.

The phase 3 VISION trial demonstrated that [¹⁷⁷Lu]Lu-PSMA-617 prolonged progression-free survival and overall survival (OS) in prostate-specific membrane antigen [PSMA]–positive metastatic castration-resistant prostate cancer (mCRPC) patients who progressed on taxane-based chemotherapy and androgen receptor–signaling inhibitors (ARSIs). The U.S. expanded-access program (EAP; NCT04825652) was opened to provide access to [¹⁷⁷Lu]Lu-PSMA-617 for eligible patients until regulatory approval was obtained. This study aimed to evaluate the efficacy and safety profile of [¹⁷⁷Lu]Lu-PSMA-617 within the EAP and compare the results with those from the VISION trial. Methods: Patients enrolled in the EAP at 4 institutions in the United States with available toxicity and outcome data were included. Outcome measures included OS, a prostate-specific antigen (PSA) response rate (RR) of at least 50%, and incidences of toxicity according to Common Terminology Criteria for Adverse Events version 5.0. Differences in baseline characteristics, outcome data, and toxicity between the EAP and VISION were evaluated using t testing of proportions and survival analyses. Results: In total, 117 patients with mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 within the EAP between May 2021 and March 2022 were eligible and included in this analysis. Patients enrolled in the EAP were more heavily pretreated with ARSI (≥2 ARSI regimens: 70% vs. 46%; P < 0.001) and had worse performance status at baseline (Eastern Cooperative Oncology Group score ≥ 2: 19% vs. 7%; P < 0.001) than VISION patients. EAP and VISION patients had similar levels of grade 3 or higher anemia (18% vs. 13%; P = 0.15), thrombocytopenia (13% vs. 8%; P = 0.13), and neutropenia (3% vs. 3%; P = 0.85) and similar PSA RRs (42% vs. 46%; P = 0.50) and OS (median: 15.1 vs. 15.3 mo; P > 0.05). Conclusion: Patients with PSMA-positive mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 within the EAP were later in their disease trajectory than VISION patients. Patients enrolled in the EAP achieved similar PSA RRs and OS and had a safety profile similar to that of the VISION trial patients.

Local officials are beginning to certify the results of this year's presidential election in a process that, so far, has been playing out quietly, in stark contrast to the tumultuous certification period four years ago that followed then-President Donald Trump's loss.

If you’ve ever tried to make a portrait that looks like the person you’re sketching, you know it’s no walk in the park. Maybe you’ve got the eyes perfectly, but then the mouth looks… well, let’s say “abstract.” So, how do the pros do it? What tools, materials, and techniques help bring out that jaw-dropping […]

The post Draw Portraits Like a Pro – Essential Tools and Materials for Photo-Realistic Results appeared first on Chart Attack.

AI search engine embraces 2024 US election with live tracker and chatbot info hub.

Outgoing firm Principal Service Solutions says incoming staffing agency Manpower may bring the workers back.

Researchers in Montreal are pointing to the benefits of bilingualism for the brain's health and efficiency — suggesting it could even help prevent diseases associated with aging, including Alzheimer's.

Canadians are watching the U.S. election results with trepidation, knowing they have no control over the outcome that will still affect them. Polling shows Vice-President Kamala Harris and former president Donald Trump are neck-and-neck. 

When university and hospital trusts were called to the UK parliament last year to answer questions on why they were not following the rules on reporting results, we saw how effective the questioning from politicians was. Those of you who watched the parliamentary session saw the pressure the university representatives were put under. Because the politicians asked […]

New research has shown that the majority of clinical trials which should be following the US law on reporting results aren’t. Less than half (41%) of clinical trial results were reported on time and 1 in 3 trials (36%) remain unreported. The research also found that clinical trials sponsored by companies are the most likely […]

SINGAPORE — Pupils who sat the PSLE will receive their results from 11am on Nov 20. The Education Ministry and Singapore Examinations and Assessment Board, in a joint statement on Nov 13, said arrangements have been made for pupils to collect their results. Pupils will get details on collection arrangements from their schools, it added. Those who are unable to collect their results from school in person can appoint someone to do so on their behalf on Nov 22. Eligible pupils will receive the Secondary 1 (S1) Option Form to select secondary schools with their PSLE results. Pupils are required to use their unique S1 personal identification number found on the top-right hand corner of the form to log in to the S1 Internet System to submit their school choices from 11.30am on Nov 20 to 3pm on Nov 26. Parents who need help with the online submission can contact the primary school before 3pm on Nov 26. Posting results will be released between Dec 18 and Dec 20 through SMS, the statement said. This information can also be accessed through the S1 Internet System or at the pupil's primary school.

European Court of Auditors

Time to Talk CINV� Video

As voters across the United States head to the polls, we speak with New York Times writer Jim Rutenberg about how Donald Trump may try to preemptively declare victory and challenge election results. The former president has ramped up claims Democrats are “a bunch of cheats” and preemptively cast doubt on a win by Vice President Kamala Harris, following a similar playbook as 2020 when he baselessly claimed the election was stolen. Rutenberg spoke to pro-Trump election officials in battleground states of Arizona, Georgia, Nevada and Pennsylvania who say they are ready to refuse to certify local election results as part of a wide-ranging effort to throw the system into disarray. Rutenberg says after the failed insurrection of January 6, 2021, many in Trump’s orbit had a clear goal for 2024: “We have to go local.” He also discusses the Electoral Count Reform Act of 2022 that makes it harder to stop the final certification of results.

When Donald Trump reenters the White House, he will be met with a newly Republican-controlled Senate, consolidating power in the hands of a party now dominated by supporters of Trump. We take a look at the results of down-ballot races for the Senate and House, and the possibilities for congressional opposition to Trump’s agenda with John Nichols, The Nation’s national affairs correspondent. Nichols notes that losing Democratic Senate candidates missed opportunities to highlight working-class voters and economic issues, likely to their detriment.

Winners from around the world, check it now...

Research by two charities finds that only 1% of disability hate crimes results in a charge

All the results from around the world as well as the latest schedule.

British bikes - all the details.

The latest bike results from around the world.

Motor racing updates from around the world, including the United States.

At the onset of the pandemic, sexually transmitted infection (STI) and medlinkHIV/medlink testing reduced, while there was a rise in positive sexually

Gentiva(R) Health Services Reports First Quarter 2010 Results

Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients

EVENT CANCELLATION NOTICE: Wisconsin Home Care Workers and Consumers to Announce Results of Largest Union Election in De

Amicus Therapeutics Announces First Quarter 2010 Financial Results and Product Pipeline Advancements

ThermoGenesis Reports Fiscal 2010 Third Quarter Results

Emdeon Reports First Quarter 2010 Results

Luminex Corporation Reports First Quarter 2010 Results

Cadence Pharmaceuticals Reports First Quarter 2010 Financial Results

PDI Reports 2010 First Quarter Financial Results

OncoGenex Reports First Quarter Financial Results

Oncothyreon reports full year and fourth quarter 2009 financial results

Sequenom Reports First Quarter 2010 Financial Results

Oncothyreon reports first quarter 2010 financial results

AMN Healthcare Announces First Quarter 2010 Results